Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | ITGAL | P20701 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14179672 | 1.00 | ECE1 (0.50) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL16750044 | 1.00 | ECE1 (0.50) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL8601335 | 0.86 | ECE1 (0.47) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL5155757 | 0.85 | ECE1 (0.49) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL10610009 | 0.85 | ECE1 (0.49) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL7351838 | 0.84 | ECE1 (0.46) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL7351840 | 0.84 | ECE1 (0.46) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL23222804 | 0.83 | ECE1 (0.47) | ECE1TGFBR1ITGB2ICAM1ITGAL | |
| SCHEMBL19729229 | 0.83 | ECE1 (0.41) | ECE1ITGB2ICAM1ITGALALDH1A1 | |
| SCHEMBL14179673 | 0.82 | CA2 (0.42) | ALDH1A1MEN1KMT2ALMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | claimed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20180111913-A1 | SUBSTITUTED BENZOFURAN DERIVATIVES AS NOVEL ANTIMYCOBACTERIAL AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-04-26 | — | — | US | disclosed |
| US-20180111913-A1 | SUBSTITUTED BENZOFURAN DERIVATIVES AS NOVEL ANTIMYCOBACTERIAL AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-04-26 | — | — | US | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | ECE1 1266/4885TGFBR1 683/4885ITGB2 2436/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | ECE1 1266/4885TGFBR1 683/4885ITGB2 2436/4885 |
| US-20180111913-A1 | SUBSTITUTED BENZOFURAN DERIVATIVES AS NOVEL ANTIMYCOBACTERIAL AGENTS | ACAT1, ACAT2, FNTB | ECE1 1764/4885TGFBR1 3183/4885ITGB2 4657/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | ECE1 1266/4885TGFBR1 683/4885ITGB2 2436/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | ECE1 1458/4885TGFBR1 128/4885ITGB2 4325/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | ECE1 3835/4885TGFBR1 3067/4885ITGB2 1459/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | ECE1 833/4885TGFBR1 4456/4885ITGB2 1797/4885 |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | ECE1 2465/4885TGFBR1 1849/4885ITGB2 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.